Can Apitegromab Approval Turn Scholar Rock (SRRK) Into the Next Biotech Multibagger?
Scholar Rock Holding Corp. (NASDAQ:SRRK) is one of the best multibagger stocks to invest in right now.
Scholar Rock Holding Corp (SRRK)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Siren L.L.C. Raymond Debbane | 9,250,005 | $327,635,177 | 16.95% | |
| 2. | Samsara BioCapital Srini Akkaraju And Michael Dybbs | 5,612,896 | $198,808,776 | 40.66% | |
| 3. | Redmile Group Jeremy Green | 3,929,039 | $139,166,561 | -11% | 14.81% |
| 4. | Hood River Capital Management David Swank | 1,974,964 | $69,953,225 | +2% | 0.98% |
| 5. | Marshall Wace LLP Paul Marshall And Ian Wace | 1,640,437 | $58,104,278 | +1% | 0.07% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $39.52 | 13,748 | $543,320.96 | 500,439 | 2025-10-06 | Filing | |
| $38.68 | 80,863 | $3,127,780.84 | 486,691 | 2025-10-06 | Filing | |
| $37.89 | 18,414 | $697,706.46 | 405,828 | 2025-10-06 | Filing | |
| $37.42 | 319,700 | $11,963,174.00 | 387,414 | 2025-10-03 | Filing | |
| $36.74 | 56,703 | $2,083,268.22 | 67,714 | 2025-10-03 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $30.67 | 3,353 | $102,846.23 | 108,964 | 2025-09-22 | Filing | |
| $33.20 | 76 | $2,522.92 | 33,914 | 2025-09-16 | Filing | |
| $32.48 | 930 | $30,202.77 | 33,990 | 2025-09-16 | Filing | |
| $33.52 | 3,178 | $106,526.56 | 112,317 | 2025-09-16 | Filing | |
| $31.17 | 2,178 | $67,880.20 | 155,464 | 2025-08-18 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,606,512 | $59,826,508 | 0.03% | |
| 2. | 443,155 | $16,503,092 | 0.02% | |
| 3. | 159,741 | $5,948,755 | 0.01% | |
| 4. | 154,901 | $5,768,513 | 0.17% | |
| 5. | 101,742 | $3,788,872 | 0.72% |
News See All
15 Best Multibagger Stocks to Invest in Right Now
Just as a single diamond can outshine a handful of pebbles, a well-chosen multibagger can transform an ordinary portfolio into an extraordinary one.
Scholar Rock (SRRK) Jumps 14% on Bargain-Hunting, Price Down 20.4% YTD
In the second quarter of the year, Scholar Rock Holding Corp. (NASDAQ:SRRK) saw its net loss widen by 89.6 percent to $110 million from $58 million in the same period last year.
Scholar Rock's Apitegromab Maintains Lean Mass In Phase 2 EMBRAZE Trial With Tirzepatide-Induced Weight Loss
Scholar Rock Holding Corporation (NASDAQ:SRRK) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in.
11 Best GLP-1 and Weight Loss Stocks to Invest in
GLP-1 medicines are a type of prescription that mimics a natural hormone that regulates blood sugar and appetite.
Scholar Rock Holding Corporation (NASDAQ:SRRK) Q2 2025 Earnings Call Transcript
Scholar Rock Holding Corporation (NASDAQ:SRRK) Q2 2025 Earnings Call Transcript August 6, 2025Scholar Rock Holding Corporation misses on earnings expectations.
Scholar Rock (SRRK) Jumps 16.6% After Successful Weight Loss Drug Trial
In a statement, Scholar Rock Holding Corporation (NASDAQ:SRRK) said the trial, which aims to assess its drug candidate apitegromab’s combination with tirzepatide, was generally well tolerated, leading...
Scholar Rock Holding Corporation (NASDAQ:SRRK) Q1 2025 Earnings Call Transcript
Scholar Rock Holding Corporation (NASDAQ:SRRK) Q1 2025 Earnings Call Transcript May 14, 2025Scholar Rock Holding Corporation misses on earnings expectations.
Scholar Rock Holding Corporation (NASDAQ:SRRK) Q4 2024 Earnings Call Transcript
Scholar Rock Holding Corporation (NASDAQ:SRRK) Q4 2024 Earnings Call Transcript February 27, 2025Scholar Rock Holding Corporation misses on earnings expectations.
10 Oversold Biotech Stocks to Buy Now
Biotechnology stocks are among the most volatile in the market, primarily due to the high risks associated with their performance.